Cellectar Biosciences, Inc.
CLRBHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeCellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. Valued at $11.5M, CLRB is a micro-cap name in its sector. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.
Market Cap
$11.5M
Beta
0.58
P/E (TTM)
—
P/E (Fwd)
-0.64
EPS (TTM)
$-3.58
EPS (Fwd)
$-1.92
ROE
-119.6%
ROA
-58.4%
Cash
$34.0M
Total Debt
$1.5M
Free CF
-$12.5M
52W Change
-69.5%
Annual Financials
Cash vs Debt
Where CLRB stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CLRB finished 56.08% below its 150-day moving average ($2.55) and 58.97% below its 200-day moving average ($2.73). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CLRB overbought or oversold?
At the October 20, 2026 close, CLRB's RSI(14) was 12.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $34.0M in cash and $1.5M in debt, CLRB maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$12.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -119.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta below 0.7, Cellectar Biosciences, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing CLRB's risk profile alongside its fundamentals and technical indicators provides a more complete picture.